Geron (GERN) to Release Quarterly Earnings on Thursday

Geron (NASDAQ:GERN) is scheduled to announce its earnings results before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Geron (NASDAQ:GERN) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.10) EPS for the quarter, meeting analysts’ consensus estimates of ($0.10). Geron had a negative net margin of 15,990.68% and a negative return on equity of 73.79%. The company had revenue of $0.88 million for the quarter, compared to analyst estimates of $0.34 million. During the same period in the prior year, the firm posted ($0.09) EPS. The company’s quarterly revenue was up 2941.4% on a year-over-year basis. On average, analysts expect Geron to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Geron Trading Down 2.6 %

NASDAQ:GERN opened at $4.15 on Thursday. The firm’s fifty day moving average is $4.37 and its 200-day moving average is $4.28. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.60 and a current ratio of 3.61. Geron has a 52 week low of $1.64 and a 52 week high of $5.34. The firm has a market cap of $2.46 billion, a P/E ratio of -11.86 and a beta of 0.50.

Analysts Set New Price Targets

A number of research firms have recently commented on GERN. Leerink Partnrs raised shares of Geron to a “strong-buy” rating in a research note on Monday, September 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Geron in a research note on Friday, August 9th. StockNews.com upgraded shares of Geron to a “sell” rating in a research report on Monday, August 5th. Leerink Partners initiated coverage on shares of Geron in a research report on Monday, September 9th. They set an “outperform” rating and a $7.00 target price on the stock. Finally, Wedbush reiterated an “outperform” rating and set a $8.00 target price on shares of Geron in a research report on Thursday, August 8th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.94.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.